Latest Administration News

Nordic Resources has completed a major acquisition of three advanced gold projects in Finland, lifting its total gold equivalent resources to 1.23 million ounces. The company also secured A$3.5 million in institutional funding and appointed a seasoned mining executive as Chairman.

Polymetals Resources has updated its June 2025 quarterly cash flow report, confirming nearly two quarters of funding and ongoing revenue from concentrate sales. The company’s financing position remains stable amid planned equity issuance.

Inhalerx Limited has drawn $247,000 from a $38.5 million funding facility to advance clinical trials for its IRX-211 and IRX-616a drug candidates, reporting positive operating cash flow for the quarter ending June 2025.

InhaleRx Limited has secured key ethics approvals and initiated manufacturing for its inhaled drug candidates targeting breakthrough cancer pain and panic disorder, supported by a $38.5 million funding facility to accelerate development.

Austal Limited has acknowledged a delayed filing of a director's interest notice due to an administrative oversight, prompting ASX scrutiny and a commitment to tighten compliance processes.

Perpetual Limited reported a 2.5% increase in assets under management to A$226.8 billion for Q4 FY25, driven by strong market performance and inflows. The company reaffirmed its expense guidance and continues to pursue the sale of its Wealth Management business.

Praemium Limited reports a 2.2% increase in funds under administration for Q4 FY25, driven by strong gains in Spectrum and SMA platforms, alongside operational upgrades including AI-driven initiatives. However, OneVue platform experiences a significant decline.

Praemium reports a 12% rise in total Australian funds under administration to $64.3 billion in Q4 FY2025, driven by strong inflows into its Spectrum platform and growth in Separately Managed Accounts. However, Powerwrap continues to face net outflows.

Insignia Financial reported a 2.6% rise in Funds Under Management and Administration to $330.3 billion, driven by record net inflows into its MLC Expand platform and a successful Master Trust transition to SS&C.

EVE Health Group has secured regulatory approval enabling prescription access for its lead products Libbo and Dyspro in Australia, setting the stage for a commercial rollout before the end of 2025.

Horizon Gold Limited has announced a $7 million non-renounceable entitlement offer alongside a $5 million placement to fund its Gum Creek Gold Project and repay debt. The offer opens on 29 July and closes on 12 August 2025.

Cleo Diagnostics reports steady progress in its ovarian cancer diagnostic test development, with clinical trial recruitment on track and strategic access to major biobanks enhancing its regulatory pathway.